Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jun 9, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on preventing and finding cervical cancer early by allowing women to perform their own screening tests in Western Uganda. The cervix is the lower part of the uterus, and certain tests can help determine if there are cells that could develop into cancer. The goal of this study is to see how effective self-administered screening, particularly using the HPV test, can be in providing cervical cancer prevention services to women in the community.
Women aged 25 to 49 who live in the Kiboga, Kyankwanzi, or Hoima districts of Uganda can participate in this study, as long as they do not have any signs of cervical cancer. Participants will take part in community health campaigns where they can access these screening tests. By joining this study, women can contribute to important research that aims to improve how cervical cancer is detected and prevented in their region.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women in the three Ugandan districts (Kiboga, Kyankwanzi and Hoima) who access screening during the community health campaigns
- • Age 25-49 years
- • Resident in the study district
- • Provision of informed consent
- Exclusion Criteria:
- • Clinical signs and symptoms of cancer of the cervix
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kampala, , Uganda
Patients applied
Trial Officials
Jeffrey Martin, MD, MPH
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials